Does Retatrutide Cause Heartburn?

Retatrutide is an investigational triple hormone receptor agonist being studied in clinical trials for obesity and type 2 diabetes, with no marketing authorisation in the UK or elsewhere. Because it acts on the GLP-1 receptor, which slows gastric emptying, gastrointestinal effects including heartburn are an expected pharmacological consequence of the drug class. This article summarises what named clinical trials have reported about digestive symptoms, who may be more susceptible, and when to seek medical advice, drawing on Phase 2 findings and comparisons with licensed medicines in the same class.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide has no UK marketing authorisation and is available only within authorised clinical trials. It is a triple GLP-1, GIP and glucagon receptor agonist, meaning gastrointestinal effects are an expected pharmacological consequence of its mechanism.

Retatrutide has no marketing authorisation in the UK or anywhere else in the world, and it is available only to participants inside an authorised clinical trial.^[2] It is an investigational medicine being studied as a potential treatment for obesity and type 2 diabetes. Unlike licensed weight-management medicines such as semaglutide (Wegovy) or tirzepatide (Mounjaro), retatrutide cannot be prescribed, dispensed or legally sold outside a formal research setting. Any product sold online under this name is not a licensed medicine and may be falsified or unsafe.

Retatrutide works by activating three hormone receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This triple agonist mechanism distinguishes it from currently licensed dual or single agonists. Because it acts on the GLP-1 receptor, which slows gastric emptying and reduces appetite, gastrointestinal effects are an expected pharmacological consequence, consistent with the broader class of incretin-based medicines.^[10][5] The UK SmPCs for licensed medicines in this class, including Wegovy and Mounjaro, document gastrointestinal adverse reactions and delayed gastric emptying as recognised class effects.^[3][4]

Because retatrutide is investigational, no dosing schedule, storage guidance or practical instructions for use can be published here. If you are interested in licensed weight-management treatments, your GP can discuss options that are currently authorised and available. The information below reflects findings from named clinical trials only and should be read as educational context about ongoing research, not as a guide to treatment.

What other gastrointestinal side effects have trials reported?

The Phase 2 NEJM trial (2023) found gastrointestinal adverse events were the most common category, including nausea, vomiting, diarrhoea and constipation. Heartburn and acid reflux are consistent with the class mechanism of delayed gastric emptying.

Clinical trials of retatrutide have reported a range of gastrointestinal side effects beyond heartburn or acid reflux, with nausea, vomiting, diarrhoea and constipation among the most commonly documented findings. In the Phase 2 trial published in the New England Journal of Medicine in 2023, gastrointestinal adverse events were the most frequently reported category across all dose groups studied.^[1] These findings are consistent with the GLP-1 receptor agonist class, where slowed gastric emptying is a known pharmacological effect that can produce a variety of digestive symptoms.

Acid reflux and heartburn (medically termed gastro-oesophageal reflux) are recognised effects of medicines that slow gastric emptying, and are documented in the UK SmPCs for licensed GLP-1-based medicines such as Wegovy and Mounjaro. Delayed gastric emptying means stomach contents remain in contact with the lower oesophageal sphincter for longer, which can increase reflux symptoms in susceptible individuals.^[11][9] Whether reflux and heartburn were reported as distinct adverse events in the retatrutide Phase 2 trial data has not been separately confirmed in the published paper; the observation here is based on the shared class mechanism. Belching, bloating and a sensation of early fullness have also been noted in trial participants.

The UK SmPCs for related licensed medicines in this class note that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, though no risk magnitude is established.^[8][3] While retatrutide does not yet have a SmPC, its shared mechanism means this signal is relevant to the class as a whole and is being monitored within ongoing trials. Participants in authorised retatrutide studies are advised to report any severe or persistent abdominal pain promptly to their trial team. Suspected side effects in a clinical trial setting should be reported to the trial team under the study protocol.

Who seems most likely to experience digestive symptoms in studies?

Gastrointestinal symptoms were more frequent at higher doses and during dose escalation, consistent with licensed GLP-1 medicines. People with pre-existing GORD or gastroparesis may be more susceptible to reflux-type symptoms.

Trial data suggest that gastrointestinal symptoms in retatrutide studies were more common at higher dose levels and during dose escalation periods, rather than being uniformly distributed across all participants. In the Phase 2 NEJM trial, adverse events including nausea and vomiting were reported more frequently in participants assigned to higher dose cohorts, and symptoms tended to be most prominent in the early weeks of treatment when doses were being increased.^[1] This dose-dependent pattern is consistent with findings from licensed GLP-1 receptor agonist medicines and is documented in their UK SmPCs.

Individuals with a pre-existing history of gastro-oesophageal reflux disease (GORD), gastroparesis or other upper gastrointestinal conditions may be more susceptible to reflux-type symptoms when taking medicines that slow gastric emptying.^[9][4] Trial protocols for investigational medicines in this class typically exclude participants with certain gastrointestinal conditions at baseline, which means the published trial populations may not fully represent people with significant pre-existing gut disease. The specific eligibility criteria for the retatrutide Phase 2 trial are set out in the published protocol and the corresponding ClinicalTrials.gov registry entry.

Age, sex and body weight have not been consistently identified as independent predictors of gastrointestinal tolerability in the available trial data, though research in this area is ongoing as larger Phase 3 programmes, including the TRIUMPH and TRANSCEND studies, continue to report.^[12] Phase 3 safety and tolerability data from these programmes have not yet been fully published in peer-reviewed form at the time of writing, so the tolerability picture described here is based primarily on Phase 2 findings. It is also worth noting that trial participants are required to meet strict eligibility criteria: individuals who are pregnant, breastfeeding or planning pregnancy are excluded from retatrutide trials, and appropriate contraception is required as a condition of participation. This means the tolerability profile in these groups remains unknown.

When should you seek medical advice about gut-related symptoms?

Trial participants must report symptoms to their trial team; people on licensed medicines should contact their GP for persistent or worsening symptoms. Severe abdominal pain, vomiting blood or signs of dehydration require urgent assessment via NHS 111 or 999.

Anyone participating in a retatrutide clinical trial who experiences gastrointestinal symptoms should report them to their trial team in the first instance, as the study protocol sets out the required reporting pathway for adverse events. Trial participants are also advised to carry their study identification details and to inform any emergency clinician that they are taking part in a clinical trial and the name of the investigational medicine, so that appropriate care decisions can be made. For people taking licensed medicines in the same class (such as semaglutide or tirzepatide), the following guidance on when to seek help is relevant and reflects standard clinical advice aligned with UK SmPC information.

Contact your GP if gastrointestinal symptoms are persistent, worsening or significantly affecting your daily life. Symptoms such as ongoing nausea, frequent vomiting, persistent diarrhoea or constipation that does not resolve with simple measures warrant a clinical review. Your GP can assess whether a dose adjustment, a change in timing of administration or a different management approach is appropriate.

Seek urgent advice via NHS 111 if you develop severe abdominal pain, particularly pain that radiates to the back, as this may indicate pancreatitis, which has been reported in association with this class of medicine.^[8][7] Seek prompt medical attention if you experience difficulty swallowing (dysphagia), vomiting blood or passing black or tarry stools, unexplained weight loss, or persistent vomiting. These are recognised red-flag features for upper gastrointestinal conditions and, in line with NICE guidance, may warrant urgent assessment or referral. Call 999 or go to your nearest accident and emergency department immediately if you experience severe vomiting that prevents you from keeping any fluids down, signs of dehydration (such as dizziness, very dark urine or confusion), or any other symptom that feels life-threatening.

Heartburn that is mild and occurs shortly after starting or increasing a dose often settles as the body adjusts. Practical measures such as eating smaller meals, avoiding lying down immediately after eating and reducing fatty or spicy foods may help. However, do not self-manage symptoms that are severe or that you are uncertain about: prompt clinical review is always the safer course.

Frequently Asked Questions